Dinesh Jothimani
Research Subjects
Dinesh Jothimani has a total of 379 co-authors. Here are the top co-authors by number of shared publications:
Mohamed Rela
21 shared publications- Mohamed Rela
The Institute of Liver Disease & Transplantation, Dr.Rela Institute & Medical Centre, Bharath Institute of Higher Education & Research, Chennai, India
8 shared publications Hemalatha Ramachandran
7 shared publications- Anand V. Kulkarni
Department of Hepatology, AIG Hospitals, Hyderabad, India
6 shared publications - Shiv Kumar Sarin
Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India
6 shared publications - Anoop Saraya
Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi, India
5 shared publications
Latest Publications
- Open Access
- 10 August 2026
- Published by The Korean Society for Transplantation in Clinical Transplantation and Research
Viscoelastic testing and blood product utilization: a prospective study on associations and predictors of high transfusion needs in living donor liver transplantation
Sharika Sriramanan, Akila Rajakumar, Amal F. Sam, Dinesh Jothimani, Deepti Sachan, Mohamed Rela. Clin Transplant Res -0001;0:. https://doi.org/10.4285/ctr.26.0024
- 10 August 2026
- Published by The Korean Society for Transplantation in Clinical Transplantation and Research
Open AccessViscoelastic testing and blood product utilization: a prospective study on associations and predictors of high transfusion needs in living donor liver transplantation
Sharika Sriramanan, Akila Rajakumar, Amal F. Sam, Dinesh Jothimani, Deepti Sachan, Mohamed Rela. Clin Transplant Res -0001;0:. https://doi.org/10.4285/ctr.26.0024
- 17 July 2026
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
Advances in the management of Hepatorenal syndrome
Purpose of review: Hepatorenal syndrome (HRS) is the extreme manifestation of acute renal dysfunction in patients with cirrhosis, resulting from systemic vasodilation and renal vasoconstriction, leading to a reduction in the glomerular filtration rate. Recent findings: The diagnostic criteria redefined diagnostic criteria for HRS-AKI (Hepatorenal syndrome -Acute kidney injury) as our understanding of disease progression has improved. This understanding of the HRS disease process guides current management, with the combination of intravascular volume expansion and vasoconstrictor therapy being the cornerstone of treatment. In addition to treatment selection, timing of treatment initiation, duration, dosage, and monitoring during treatment are decisive factors in HRS outcomes. Pathogenesis of HRS-AKI may be different in patients with acute-on-chronic liver failure (ACLF) in comparison to decompensated cirrhosis. Unfortunately, outcomes remain poor with medical therapies alone and a high risk of disease recurrence exists for HRS-AKI with persistence of the cirrhotic milieu. Liver transplantation remains the only definitive treatment of HRS-AKI. Given the critical nature of HRS-AKI, a multidisciplinary approach involving hepatologists, nephrologists, and intensive care physicians is essential for optimal clinical management. Summary: Patients with HRS-AKI should be managed ideally in tertiary care centers and referred for liver transplantation promptly when eligible.
- 17 July 2026
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
Advances in the management of Hepatorenal syndrome
Purpose of review: Hepatorenal syndrome (HRS) is the extreme manifestation of acute renal dysfunction in patients with cirrhosis, resulting from systemic vasodilation and renal vasoconstriction, leading to a reduction in the glomerular filtration rate. Recent findings: The diagnostic criteria redefined diagnostic criteria for HRS-AKI (Hepatorenal syndrome -Acute kidney injury) as our understanding of disease progression has improved. This understanding of the HRS disease process guides current management, with the combination of intravascular volume expansion and vasoconstrictor therapy being the cornerstone of treatment. In addition to treatment selection, timing of treatment initiation, duration, dosage, and monitoring during treatment are decisive factors in HRS outcomes. Pathogenesis of HRS-AKI may be different in patients with acute-on-chronic liver failure (ACLF) in comparison to decompensated cirrhosis. Unfortunately, outcomes remain poor with medical therapies alone and a high risk of disease recurrence exists for HRS-AKI with persistence of the cirrhotic milieu. Liver transplantation remains the only definitive treatment of HRS-AKI. Given the critical nature of HRS-AKI, a multidisciplinary approach involving hepatologists, nephrologists, and intensive care physicians is essential for optimal clinical management. Summary: Patients with HRS-AKI should be managed ideally in tertiary care centers and referred for liver transplantation promptly when eligible.
Chronic kidney disease in cirrhosis: a study of inpatients from a global perspective
Background: The prevalence of chronic kidney disease (CKD), defined as a glomerular filtration rate (GFR) of 3 months, is rising in the global population. Objective: To assess the global prevalence of CKD in cirrhosis and how it impacts the prognosis of these patients. Design: The Chronic Liver Disease Evolution and Registry for Events and Decompensation consortium prospectively enrolled non-electively admitted cirrhosis patients from 127 sites globally, each with up to 100 patients. Data collected were demographics, comorbid conditions, cirrhosis history, hospital course and patient outcomes. Patients were divided into those with (CKD+) and without CKD (CKD–) and compared. We also compared patients from different World Bank income strata. Results: Of 7040 inpatients enrolled, the global prevalence of CKD was 18.17%, with the highest prevalence observed in high-income countries (HICs), which paralleled their higher prevalence of metabolic syndrome. CKD+ patients had lower median enrolment GFR (32 (21, 44) mL/min/1.73 m 2 ) when compared with CKD– patients (88 (63, 117) mL/min/1.73 m 2 , p<0.0001), associated with a more complex history of cirrhosis complications, with ascites occurring in 76.5% of CKD+ versus 61.1% of patients with CKD- (p<0.0001). The most common in-hospital complication was the development of AKI (59.4%) in CKD+ versus 27% in CKD– patients (p<0.0001). CKD was associated with higher in-hospital and 30-day postdischarge mortality (both p<0.0001). Conclusions: The presence of CKD negatively impacts the prognosis of admitted patients with cirrhosis in a global cohort. Meticulous management of ascites and lifestyle changes, especially in HICs, may improve the outcome of these patients.
Chronic kidney disease in cirrhosis: a study of inpatients from a global perspective
Background: The prevalence of chronic kidney disease (CKD), defined as a glomerular filtration rate (GFR) of 3 months, is rising in the global population. Objective: To assess the global prevalence of CKD in cirrhosis and how it impacts the prognosis of these patients. Design: The Chronic Liver Disease Evolution and Registry for Events and Decompensation consortium prospectively enrolled non-electively admitted cirrhosis patients from 127 sites globally, each with up to 100 patients. Data collected were demographics, comorbid conditions, cirrhosis history, hospital course and patient outcomes. Patients were divided into those with (CKD+) and without CKD (CKD–) and compared. We also compared patients from different World Bank income strata. Results: Of 7040 inpatients enrolled, the global prevalence of CKD was 18.17%, with the highest prevalence observed in high-income countries (HICs), which paralleled their higher prevalence of metabolic syndrome. CKD+ patients had lower median enrolment GFR (32 (21, 44) mL/min/1.73 m 2 ) when compared with CKD– patients (88 (63, 117) mL/min/1.73 m 2 , p<0.0001), associated with a more complex history of cirrhosis complications, with ascites occurring in 76.5% of CKD+ versus 61.1% of patients with CKD- (p<0.0001). The most common in-hospital complication was the development of AKI (59.4%) in CKD+ versus 27% in CKD– patients (p<0.0001). CKD was associated with higher in-hospital and 30-day postdischarge mortality (both p<0.0001). Conclusions: The presence of CKD negatively impacts the prognosis of admitted patients with cirrhosis in a global cohort. Meticulous management of ascites and lifestyle changes, especially in HICs, may improve the outcome of these patients.
- 27 April 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Machine Learning Models Using Hospital Admission Characteristics Do Not Optimally Predict Nosocomial Infection Development in a Global Cirrhosis Cohort
INTRODUCTION: Nosocomial infections (NIs) in cirrhosis are associated with high mortality but could be preventable. Logistic regression (LR) models have failed to identify high-risk patients. We aimed to develop machine learning (ML) models to predict NI. METHODS: The CLEARED consortium consists of prospectively enrolled cirrhosis inpatients from >120 centers. Using day-of-admission clinical data, 3 ML approaches (random forest [RF], extreme gradient boosting, and neural networks [NNs]) were used to predict NI. Data were split 80:20 for training and testing stratified by the outcome. Models were compared using area under the receiver operating characteristic curve (AUC). RESULTS: In total, 8,263 patients (55.90 ± 13.34 years; 64.1% men) from 127 centers in 37 countries were included. NI developed in 869 (10.5%), a median of 6 (4–11) days of postadmission. Major NIs were respiratory (29.6%) and urinary tract infection (15.7%), and spontaneous bacterial peritonitis (13.5%). NIs occurred more frequently in patients from low/low-middle income countries and those with severe liver disease, alcohol etiology, and admission infections. NIs were associated with inpatient mortality (31.9% vs 8.1%, P < 0.001) and liver transplantation (4.8% vs 1.9%, P < 0.001). Although the RF model (AUC 0.69) showed good calibration (Brier score 0.09), outperforming extreme gradient boosting, neural network, and LR models (AUC 0.66 for all; LR comparison P = 0.043), no model achieved AUC ≥0.80 for clinical utility. At 10% predicted probability threshold, the RF model demonstrated only 75.4% sensitivity, 52.9% specificity, and 15.9% positive predictive value (PPV). DISCUSSION: NIs cannot be accurately predicted from day-of-admission data using ML models, even in a large, prospective, global cirrhosis cohort. Every hospitalized patient with cirrhosis should receive protocolized infection control measures.
- 27 April 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Machine Learning Models Using Hospital Admission Characteristics Do Not Optimally Predict Nosocomial Infection Development in a Global Cirrhosis Cohort
INTRODUCTION: Nosocomial infections (NIs) in cirrhosis are associated with high mortality but could be preventable. Logistic regression (LR) models have failed to identify high-risk patients. We aimed to develop machine learning (ML) models to predict NI. METHODS: The CLEARED consortium consists of prospectively enrolled cirrhosis inpatients from >120 centers. Using day-of-admission clinical data, 3 ML approaches (random forest [RF], extreme gradient boosting, and neural networks [NNs]) were used to predict NI. Data were split 80:20 for training and testing stratified by the outcome. Models were compared using area under the receiver operating characteristic curve (AUC). RESULTS: In total, 8,263 patients (55.90 ± 13.34 years; 64.1% men) from 127 centers in 37 countries were included. NI developed in 869 (10.5%), a median of 6 (4–11) days of postadmission. Major NIs were respiratory (29.6%) and urinary tract infection (15.7%), and spontaneous bacterial peritonitis (13.5%). NIs occurred more frequently in patients from low/low-middle income countries and those with severe liver disease, alcohol etiology, and admission infections. NIs were associated with inpatient mortality (31.9% vs 8.1%, P < 0.001) and liver transplantation (4.8% vs 1.9%, P < 0.001). Although the RF model (AUC 0.69) showed good calibration (Brier score 0.09), outperforming extreme gradient boosting, neural network, and LR models (AUC 0.66 for all; LR comparison P = 0.043), no model achieved AUC ≥0.80 for clinical utility. At 10% predicted probability threshold, the RF model demonstrated only 75.4% sensitivity, 52.9% specificity, and 15.9% positive predictive value (PPV). DISCUSSION: NIs cannot be accurately predicted from day-of-admission data using ML models, even in a large, prospective, global cirrhosis cohort. Every hospitalized patient with cirrhosis should receive protocolized infection control measures.
- 20 January 2026
- Published by Springer Nature
- p. 91-113
Cardiac Issues in Liver transplantation
- 20 January 2026
- Published by Springer Nature
- p. 733-752
Post–Liver Transplant Viral Infections (Non-hepatotropic)
- 20 January 2026
- Published by Springer Nature
- p. 733-752
Post–Liver Transplant Viral Infections (Non-hepatotropic)
- 20 January 2026
- Published by Springer Nature
- p. 679-697
Liver Allograft Rejection
- 20 January 2026
- Published by Springer Nature
- p. 375-397
Autoimmune Hepatitis